Pfizer Case Study
Pfizer – Written Case Report
Prepared by:
BAMG 456-023: Strategic Management & Business Policy (Fall 2012)
Table of Contents: 1. Part One: Evaluation of the External Environment a. Introduction 4 b. Opportunities and Threats 6 i. Assessment of Societal (Remote) Environment ii. Assessment of Industry (Task) Environment iii. Assessment of Competition (Bryan Jenkins) iv. Overall Opportunities and Threats and Score 2. Part Two: Evaluation of the Internal Environment # c. Financial Management Analysis # v. Profitability vi. Analysis of Income Statement, Balance Sheet, Cash Flows vii. Ratio Analysis, Z-value, g* viii. Inventory Turns, Credit Ratings ix. Financial Problem or Success Statement d. Analysis of Marketing Position # x. Sales – Long term trend xi. Market Share vs. Industry and Competitors for 5 Years xii. Marketing Tactics xiii. Marketing Problem or Success Statement e. Analysis of Management & Management Effectiveness # xiv. Identification of Structure and Top Management xv. Top Management and Executive Compensation xvi. Stock Price Performance vs. Benchmarks xvii. Direction of Top Management Team # xviii. Evaluation of Mission, Vision, or Corporate Goals xix. Management Performance Assessment xx. Management Problem or Success Statement f. Assessment of MIS and Information Age Readiness # 3. Part Three: Strategic Position # g. Current Core Competencies h. Current Distinctive Competencies i. Current Corporate Level Long-Term Strategies/Tactics j. Current Corporate Level Short-Term Strategies/Tactics k. Current SBU Level Strategies and Tactics l. Top Five Performance Indicators 4. Part Four: Overall
Prepared by:
BAMG 456-023: Strategic Management & Business Policy (Fall 2012)
Table of Contents: 1. Part One: Evaluation of the External Environment a. Introduction 4 b. Opportunities and Threats 6 i. Assessment of Societal (Remote) Environment ii. Assessment of Industry (Task) Environment iii. Assessment of Competition (Bryan Jenkins) iv. Overall Opportunities and Threats and Score 2. Part Two: Evaluation of the Internal Environment # c. Financial Management Analysis # v. Profitability vi. Analysis of Income Statement, Balance Sheet, Cash Flows vii. Ratio Analysis, Z-value, g* viii. Inventory Turns, Credit Ratings ix. Financial Problem or Success Statement d. Analysis of Marketing Position # x. Sales – Long term trend xi. Market Share vs. Industry and Competitors for 5 Years xii. Marketing Tactics xiii. Marketing Problem or Success Statement e. Analysis of Management & Management Effectiveness # xiv. Identification of Structure and Top Management xv. Top Management and Executive Compensation xvi. Stock Price Performance vs. Benchmarks xvii. Direction of Top Management Team # xviii. Evaluation of Mission, Vision, or Corporate Goals xix. Management Performance Assessment xx. Management Problem or Success Statement f. Assessment of MIS and Information Age Readiness # 3. Part Three: Strategic Position # g. Current Core Competencies h. Current Distinctive Competencies i. Current Corporate Level Long-Term Strategies/Tactics j. Current Corporate Level Short-Term Strategies/Tactics k. Current SBU Level Strategies and Tactics l. Top Five Performance Indicators 4. Part Four: Overall
Bibliography: "Background Information - ClinicalTrials.gov." Background Information - ClinicalTrials.gov. N.p., n.d. Web. 05 Nov. 2012. <http://clinicaltrials.gov/ct2/info/und>. "The Leader in Press Release Distribution." Press Release Distribution, Financial Disclosure, Online Newsrooms, PR, Public Relations, Investor Relations, EDGAR Filing, XBRL, Breaking News, Business News, Financial News. N.p., n.d. Web. 05 Nov. 2012. <http://www.businesswire.com/>. "Pfizer Inc." PFE Executive Compensation. N.p., n.d. Web. 05 Nov. 2012. <http://insiders.morningstar.com/trading/executive-compensation.action?t=PFE>. "Pfizer Moves Supply Chain to Cloud." Financial Times. N.p., n.d. Web. 05 Nov. 2012. <http://www.ft.com/cms/s/0/1608e5d6-fc59-11e1-ac0f-00144feabdc0.html%20>. Pfizer. N.p., n.d. Web. <http://www.pfizer.com/home/>. "Pfizer Sees Sustained Long-Term Growth Driven By Innovative Products, Strong R&D Pipeline and Operating Efficiencies." Pfizer Sees Sustained Long-Term Growth Driven By Innovative Products, Strong R&D Pipeline... N.p., n.d. Web. 05 Nov. 2012. <http://www.prnewswire.com/news-releases/pfizer-sees-sustained-long-term-growth-driven-by-innovative-products-strong-rd-pipeline-and-operating-efficiencies-66636992.html>. "Top Selling Drugs Are About to Lose Patent Protection." DailyFinance.com. N.p., n.d. Web. 05 Nov. 2012. <http://www.dailyfinance.com/2011/02/27/top-selling-drugs-are-about-to-lose-patent-protection-ready/>.